Caris Life Sciences Lags Value Peers with 68.1x Forward P/E, D Grade
Caris Life Sciences holds a Zacks Rank of #4 and a Style Score Value grade of D, with a forward P/E of 68.11, PEG ratio of 1.75 and P/B ratio of 12.15. Its valuation metrics lag BrightSpring Health Services’ forward P/E of 30.54, PEG of 0.65 and P/B of 4.
1. Caris Life Sciences Zacks Rank and Value Grade
Caris Life Sciences carries a Zacks Rank of #4, reflecting weaker earnings estimate revisions, and earned a Style Score Value grade of D, highlighting valuation challenges for investors.
2. Forward Valuation Metrics
The company reports a forward P/E ratio of 68.11, a PEG ratio of 1.75 that incorporates expected earnings growth, and a P/B ratio of 12.15, indicating a premium market valuation relative to its fundamentals.
3. Comparison with BrightSpring Health Services
BrightSpring outperforms on valuation metrics with a forward P/E of 30.54, PEG ratio of 0.65 and P/B ratio of 4, securing a Value grade of B and positioning it as the stronger value option.